Relay Therapeutics, Inc. Stock Price, News & Analysis

Relay Therapeutics announced promising interim clinical data for RLY-4008, a selective FGFR2 inhibitor, presented at the AACR-NCI-EORTC Molecular Targets Conference. In a first-in-human trial, 80% of patients showed tumor shrinkage, with three of six cholangiocarcinoma patients achieving confirmed partial responses. The drug exhibited a favorable safety profile, with minimal off-target toxicities. Relay plans to finalize a recommended Phase 2 dose and expand cohorts by the end of 2021, indicating a strong potential market entry for this targeted therapy.

Relay Therapeutics presented new preclinical data for RLY-2608, a targeted PI3Kα inhibitor, at the virtual AACR-NCI-EORTC conference. This novel allosteric inhibitor demonstrated preferential binding to mutant PI3Kα without affecting wild-type forms, achieving significant tumor regression in animal models. RLY-2608 could potentially address over 100,000 patients annually in the U.S. Its targeted approach may double the patient population compared to existing therapies. The first-in-human trial is expected in H1 2022, indicating a promising development in precision oncology.

Relay Therapeutics (Nasdaq: RLAY) announced the presentation of initial clinical data for RLY-4008 and preclinical data for RLY-2608 at the AACR-NCI-EORTC Molecular Targets Conference from October 7-10, 2021. RLY-4008 is a selective FGFR2 inhibitor currently in a first-in-human trial, while RLY-2608, a pan-mutant PI3Kα inhibitor, is set to start its first trial in early 2022. A conference call will occur on October 8 to discuss the results.

Relay Therapeutics (Nasdaq: RLAY) has selected RLY-2608 as a development candidate for PI3Kα mutant inhibitors and plans to initiate a first-in-human study in H1 2022. RLY-2608 effectively inhibits mutants H1047X, E542X, and E545X, impacting over 100,000 patients annually in the U.S. The company reported Q2 2021 financial results, revealing a net loss of $193.4 million. Additionally, Relay has partnered with EQRx to develop oncology medicines, sharing development costs and profits equally. The company expects sufficient cash to fund operations into 2024.

Relay Therapeutics (Nasdaq: RLAY) announced plans to report its second quarter 2021 financial results on August 12, 2021, after market closure. The company will not hold a teleconference to discuss these results. Relay Therapeutics is a clinical-stage precision medicine firm focused on transforming drug discovery using its innovative Dynamo™ platform, targeting oncology and genetic diseases. The company aims to tackle challenging protein targets through an integration of computational and experimental technologies.

Relay Therapeutics (Nasdaq: RLAY) will participate in two upcoming fireside chats: at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 pm ET, and at the JMP Securities Life Science Conference on June 17, 2021, at 10:30 am ET. These discussions will be webcast live and accessible via the Investor page of Relay's website. Archived replays will be available for 90 days post-event. Relay Therapeutics, a clinical-stage precision medicine company, aims to enhance drug discovery using its Dynamo™ platform focused on oncology and genetic diseases.

Relay Therapeutics (Nasdaq: RLAY) will participate in a fireside chat at the Cowen 2nd Annual Virtual Oncology Innovation Summit on May 20, 2021, at 11:20 AM ET. The event will be webcast live and accessible via the Investor page of Relay's website. A replay of the chat will be available for 90 days post-event, until August 18, 2021. Relay Therapeutics focuses on precision medicine, using its Dynamo™ platform to enhance drug discovery for challenging protein targets, particularly in oncology and genetic diseases.

Relay Therapeutics reported its first quarter 2021 financial results, highlighting a cash reserve of approximately $726.1 million, up from $678.1 million at the end of 2020, ensuring funding into 2024. The company focuses on advancing its clinical programs, including RLY-1971 and RLY-4008, and has made its first acquisition of ZebiAI to enhance its Dynamo™ platform. However, the net loss widened to $42.2 million, compared to $24.9 million in Q1 2020, with increased R&D and G&A expenses.

Relay Therapeutics (Nasdaq: RLAY) has appointed Dr. Patrick Riley as the senior vice president of artificial intelligence, enhancing its computational strength in drug discovery. With 15 years of experience from Google, Dr. Riley will spearhead a computational team focused on applying AI to drug development. His expertise in machine learning and data science is expected to strengthen Relay's innovative approach, particularly following its recent acquisition of ZebiAI. The company aims to tackle challenging protein targets to deliver transformative therapies.